A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Détail de l'auteur
Auteur Rémy de Mil
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Affiner la rechercheTotally implanted venous access-associated adverse events in oncology : results from a prospective 1-year surveillance programme / Thomas Vermeulin in Bulletin du cancer, vol. 105, 11 (Novembre 2018)
[article]
in Bulletin du cancer > vol. 105, 11 (Novembre 2018) . - p. 1003-1011
Titre : Totally implanted venous access-associated adverse events in oncology : results from a prospective 1-year surveillance programme Type de document : article de périodique Auteurs : Thomas Vermeulin ; Mélodie Lucas ; Hélène Marini ; Frédéric Di Fiore ; Agnès Loeb ; Marion Lottin ; Hervé Daubert ; Rémy de Mil ; Véronique Merle Année de publication : 2018 Article en page(s) : p. 1003-1011 Note générale : https://doi.org/10.1016/j.bulcan.2018.09.005 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]:D:Dispositifs d'accès vasculaires:Dispositifs d'accès vasculaires / effets indésirables
[Thésaurus Mesh]:T:Tumeurs hématologiques:Tumeurs hématologiques / traitement médicamenteux
[Thésaurus Mesh]Hospitalisation
[Thésaurus Mesh]Qualité des soins de santé
[Thésaurus Mesh]Surveillance post-commercialisation des produits de santé
[Thésaurus Mesh]Systèmes d'information hospitaliers
[Thésaurus Mesh]TumeursMots-clés : Dispositifs d'accès vasculaires / effets indésirables Qualité des soins de santé Surveillance post-commercialisation des produits de santé Incident critique en soins de santé Infections sur cathéters Facteurs de risque Métastase tumorale Tumeurs hématologiques / traitement médicamenteux systèmes d'information hospitaliers hospitalisation Résumé : Introduction
During the last decade, most studies on totally implanted venous access-associated adverse events (TIVA-AE) were conducted retrospectively and/or were based on a limited sample size. The aim of our survey was two-fold: to estimate the incidence of TIVA-AE and to identify risk factors in patients with cancer.
Methods
Data from our routine surveillance of TIVA-AE were collected prospectively between October 2009 and January 2011 in two oncology referral centers in Northern France. The open cohort under surveillance during the same time period was reconstituted retrospectively using data from the hospital information systems. Incidences of first TIVA-AE per 1000 TIVA-days were calculated. Risk factors were identified using multivariate logistic regressions.
Results
We included 2286 cancer patients, corresponding to 582,347 TIVA-days. Among the 133 first TIVA-AE observed (incidence 0.23 per 1000 TIVA-days [0.19–0.27]), there were 50 infectious AE (incidence 0.09 [0.06–0.11]) and 83 non-infectious AE (incidence 0.14 [0.11–0.17]). Compared to non-metastatic solid cancers, metastatic cancers (aOR=2.3 [0.9–6.0]), and hematologic malignancies (aOR=3.2 [1.1–8.8]) tended to be associated with a higher risk of infectious TIVA-AE (P=0.087). Solid cancer type was associated with non-infectious TIVA-AE (P=0.030), especially digestive cancers.
Discussion
We report accurate estimations of TIVA-AE incidences in one of the largest populations among previously published studies. As in previous studies, metastatic cancers and hematologic malignancies tended to be associated with a higher risk of infectious TIVA-AE. Further studies are warranted to confirm the effect of digestive cancers.Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité B Périodique Erasme - périodiques Périodiques Disponible